Discovery of new chemotypes of dual 5-HT2A/D2 receptor antagonists with a strategy of drug design methodologies
Aim: Through the application of structure- and ligand-based methods, the authors aimed to create an integrative approach to developing a computational protocol for the rational drug design of potent dual 5-HT2A/D2 receptor antagonists without off-target activities on H1 receptors. Materials & methods: Molecular dynamics and virtual docking methods were used to identify key interactions of the structurally diverse antagonists in the binding sites of the studied targets, and to generate their bioactive conformations for further 3D-quantitative structure-activity relationship modeling. Results & conclusion: Toward the goal of finding multi-potent drugs with a more effective and safer profile, the obtained results led to the design of a new set of dual antagonists and opened a new perspective on the therapy for complex brain diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Future medicinal chemistry - 14(2022), 13 vom: 30. Juli, Seite 963-989 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Radan, Milica [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
333DO1RDJY |
|---|
| Anmerkungen: |
Date Completed 21.06.2022 Date Revised 06.09.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/fmc-2021-0340 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341958093 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341958093 | ||
| 003 | DE-627 | ||
| 005 | 20231226012952.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/fmc-2021-0340 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1139.xml |
| 035 | |a (DE-627)NLM341958093 | ||
| 035 | |a (NLM)35674007 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Radan, Milica |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Discovery of new chemotypes of dual 5-HT2A/D2 receptor antagonists with a strategy of drug design methodologies |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.06.2022 | ||
| 500 | |a Date Revised 06.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: Through the application of structure- and ligand-based methods, the authors aimed to create an integrative approach to developing a computational protocol for the rational drug design of potent dual 5-HT2A/D2 receptor antagonists without off-target activities on H1 receptors. Materials & methods: Molecular dynamics and virtual docking methods were used to identify key interactions of the structurally diverse antagonists in the binding sites of the studied targets, and to generate their bioactive conformations for further 3D-quantitative structure-activity relationship modeling. Results & conclusion: Toward the goal of finding multi-potent drugs with a more effective and safer profile, the obtained results led to the design of a new set of dual antagonists and opened a new perspective on the therapy for complex brain diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a 3D-QSAR | |
| 650 | 4 | |a 5-HT2A | |
| 650 | 4 | |a D2 | |
| 650 | 4 | |a H1 | |
| 650 | 4 | |a fragment-based drug design | |
| 650 | 4 | |a molecular docking | |
| 650 | 4 | |a molecular dynamics simulations | |
| 650 | 7 | |a Ligands |2 NLM | |
| 650 | 7 | |a Serotonin |2 NLM | |
| 650 | 7 | |a 333DO1RDJY |2 NLM | |
| 700 | 1 | |a Djikic, Teodora |e verfasserin |4 aut | |
| 700 | 1 | |a Nikolic, Katarina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future medicinal chemistry |d 2009 |g 14(2022), 13 vom: 30. Juli, Seite 963-989 |w (DE-627)NLM194822109 |x 1756-8927 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:13 |g day:30 |g month:07 |g pages:963-989 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/fmc-2021-0340 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 13 |b 30 |c 07 |h 963-989 | ||